Orexigen Therapeutics Files For IPO

San Diego-based Orexigen Therapeutics, a biopharmaceutical firm focused on treatments of central nervous system disorders and obesity has filed for an IPO. The firm said Tuesday afternoon in a filing with the SEC that it is looking to raise up to $86.25M in an IPO on the Nasdaq Global Market under the symbol OREX. Orexigen is venture backed by Domain Associates, Kleiner Perkins Caufield & Byers, Sofinnova Venture Partners, BA Venture Partners, Montreax Equity Partners, Morgenthaler Partners, and others, and has raised $76.0M in venture capital since January of 2004.